


# Introduction to the NIH Common Fund Somatic Cell Genome Editing (SCGE) Program



PJ Brooks, PhD

NIH SCGE Program Coordinator

National Center for Advancing Translational Sciences (NCATS)

<https://commonfund.nih.gov/editing>



National Institutes of Health  
Office of Strategic Coordination - The Common Fund

# The Common Fund Moves the NIH Mission Forward Faster



The Common Fund

- Supports **bold, five-year, goal-driven** scientific programs that **catalyze** biomedical research
- **Complements the missions** of the NIH Institutes and Centers
- Addresses **emerging opportunities and challenges** that **no single IC** can address on its own
- Is supported by the Office of the NIH Director and managed in **partnership with the Institutes and Centers**




# SCGE Phase I (2018-2023) was Designed to Fill Gaps Identified by Experts at 2017 NIH Workshop



The Common Fund

- Needs Identified in 2017 Phase I Planning Workshop:
  - More informative, predictive animal models
  - Assays and technologies to detect unintended consequences of genome editing
  - More effective delivery vehicles for clinically relevant cells and tissues
  - Safer, more specific editors
  - Access to advanced technologies



# Initiative 1: Animal Reporter & Testing Centers



The Common Fund

## Goals:

- Develop and validate reporter animals to allow quantitative evaluation of targeted genome editing in all cells and tissues, including germ cells.
- Establish assays and standard operating procedures (SOPs) to detect genome editing in cells of the wild type animals.
- Evaluate the ability of delivery technologies developed by SCGE Delivery Technologies investigators to deliver genome editing tools to target cells and tissues

## Progress to Date:

- Generated multiple lines of fluorescent reporter mice
- Designed reporter pigs and NHPs
- Validated several new delivery methods
- Collaborating to map tropism of popular AAV serotypes

Organism	Editing events detected	Primary readout	Secondary readout	Editors	PIs <sup>a</sup>
Mouse	NHEJ, HDR, off-target cutting	Fluorescent signal in situ	Luciferase	SpyCas9, SauCas9, Cas12a	J. D. Heaney, M. E. Dickinson, W. R. Lagor
Mouse	NHEJ, HDR, base editing, PNA	Fluorescent signal in situ	Luciferase, Nal symporter	SpyCas9, SauCas9, Cas12a, Nme2Cas9, CjeCas9, ABE, CBE, PNA	S. A. Murray, C. M. Lutz
Pig	NHEJ, HDR	Fluorescent signal	Nal symporter	SpyCas9, SauCas9, Cas12a, ABE	D. F. Carlson; K. D. Wells, R.S. Prather
Macaque	NHEJ, HDR, C base editing	Fluorescent signal	Luciferase	SpyCas9, SauCas9, Cas12a, CBE	J. D. Hennebold; A. F. Tarantal, D. J. Segal
Marmoset	NHEJ	Akaluciferase	Fluorescence	SpyCas9, SauCas9, Nme2Cas9, Cas12a, ABE	G. Feng; A. F. Tarantal, D. J. Segal

# Initiative 2: Biological Effects and In Vivo Monitoring



The Common Fund

## Goals:

- Develop and validate of human tissue- and cell-based platforms for predicting adverse consequences of genome editing
- Support the development of tools and technologies that will enable longitudinal monitoring and tracking of genome edited cells in humans to better assess the safety and efficacy of genome editing therapies

## Progress to Date:

- Demonstrated unintended consequences in multiple human cell systems
- Improved off-target assays
- Designed assays for long-term tracking

nature biotechnology

Explore content ▾ Journal information ▾ Publish with us ▾

nature > nature biotechnology > articles > article

Article | Published: 15 June 2020

### CHANGE-seq reveals genetic and epigenetic effects on CRISPR–Cas9 genome-wide activity

Cicera R. Lazzarotto, Nikolay L. Malinin, Yichao Li, Ruochi Zhang, Yang Yang, GaHyun Lee, Eleanor Cowley, Yanghua He, Xin Lan, Kasey Jividen, Varun Katta, Natalia G. Kolmakova, Christopher T. Petersen, Qian Qi, Evgheni Strelcov, Samantha Maragh, Giedre Krenciute, Jian Ma, Yong Cheng & Shengdar Q. Tsai

*Nature Biotechnology* 38, 1317–1327(2020) | Cite this article

8238 Accesses | 10 Citations | 67 Altmetric | Metrics

ELSEVIER

Current Opinion in Biomedical Engineering

Volume 16, December 2020, Pages 72-81

### Multicellular systems to translate somatic cell genome editors to human

Victor Hernandez-Gordillo<sup>1, 2, a</sup>, Thomas Caleb Casolaro<sup>1, 2, a</sup>, Mo R. Ebrahimkhani<sup>1, 2, 3, 4</sup>, Samira Kiani<sup>1, 2</sup>

Show more ▾

+ Add to Mendeley Share Cite

# Initiative 3: New and Improved Delivery Systems



The Common Fund

## Goals:

- Development of safe and effective technologies to deliver genome editing machinery into a diverse set of disease-relevant somatic cells and tissues

## Progress to Date:

- Generated several new delivery methods including improved AAVs and NPs
- Upon achievement of in-house, *in vivo* proof of concept, the delivery systems are independently validated by SCGE-funded animal testing centers.

**nature nanotechnology**

Explore content ▾ Journal information ▾ Publish with us ▾

nature > nature nanotechnology > letters > article

Letter | Published: 09 September 2019

**A biodegradable nanocapsule delivers a Cas9 ribonucleoprotein complex for in vivo genome editing**

Guojun Chen, Amr A. Abdeen, Yuyuan Wang, Pawan K. Shahi, Samantha Robertson, Ruosen Xie, Masatoshi Suzuki, Bikash R. Pattnaik, Krishanu Saha & Shaoqin Gong

*Nature Nanotechnology* **14**, 974–980(2019) | Cite this article

15k Accesses | 65 Citations | 15

**nature communications**

Explore Content ▾ Journal Information ▾ Publish With Us ▾

nature > nature communications > articles > article

Article | Open Access | Published: 28 October 2019

**Engineered amphiphilic peptides enable delivery of proteins and CRISPR-associated nucleases to airway epithelia**

Sateesh Krishnamurthy, Christine Wohlford-Lenane, Suhas Kandimalla, Gilles Sartre, David K. Meyerholz, Vanessa Théberge, Stéphanie Hallée, Anne-Marie Duperré, Thomas Del'Guidice, Jean-Pascal Lepetit-Stoffaès, Xavier Barbeau, David Guay & Paul B. McCray Jr.

*Nature Communications* **10**, Article number: 4906 (2019) | Cite this article

8996 Accesses | 19 Citations | 61 Altmetric | Metrics

# Initiative 4: Expanding the Human Genome Engineering Repertoire



The Common Fund

## Goals:

- Develop novel and optimized alternative genome editing platforms

## Progress to Date:

- Improved base editors
- Discovered mitochondrial DNA, PRIME and cas $\Phi$  editors

Science Contents News Careers Journals

Read our COVID-19 research and news.

SHARE REPORT

CRISPR-Cas $\Phi$  from huge phages is a hypercompact genome editor

Patrick Pausch<sup>1,2,\*</sup>, Basem Al-Shayeb<sup>1,3,\*</sup>, Ezra Bisom-Rapp<sup>4</sup>, Connor A. Tsuchida<sup>1,5</sup>, Zheng Li<sup>6</sup>, Brady F. Cress<sup>1,2</sup>, Gavin J. Knott<sup>1,2,7</sup>, Steven E. Jacobsen<sup>6,8</sup>, Jillian F. Banfield<sup>1,9</sup>, Jennifer A. Doudna<sup>1,2,8,10,11,12,†</sup>

This screenshot shows the top portion of a Science journal article page. It includes the journal's navigation menu, a red banner for COVID-19 research, and the article's title and author list.

Science Contents News Careers Journals

A new way to modify DNA, "prime editor" couples two enzymes, Cas9 (blue) and reverse transcriptase (red) with a guide RNA (green) that takes the complex to a specific place on DNA's double helix (yellow and purple) and holds the code for an insertion of new DNA at that spot. PEYTON RANDOLPH

26

New 'prime' genome editor could surpass CRISPR

By Jon Cohen | Oct. 21, 2019, 11:00 AM

This screenshot shows a different view of the same article, featuring a diagram of the prime editor mechanism, the article title, and the author information.

# Initiative 5: Dissemination and Coordination



The Common Fund

## Goals:

- Enable close interactions and efficient lines of communication between the SCGE Phase I Awardees
- Develop and disseminate a SCGE Toolkit for Therapeutic Genome Editing present resources generated from the Consortium in an intuitive and readily accessible online interface.

## Progress to Date:

- Coordinated Marker Paper
- Internally beta-testing the SCGE Toolkit
- Awarded 15 collaborative projects among SCGE Phase I Awardees to exchange, cross-test and evaluate SCGE-funded technologies



About The SCGE

Goals by Initiatives

Policies

News & Events

Resources

Publications



## nature

Explore Content

Journal Information

Publish With Us

nature > perspectives > article

Perspective | Open Access | Published: 07 April 2021

### The NIH Somatic Cell Genome Editing program

Krishanu Saha, Erik J. Sontheimer, [...] The SCGE Consortium


Nature 592, 195–204(2021) | Cite this article

186 Altmetric | Metrics

# SCGE Program Timeline



The Common Fund



Phase II can **continue to address the needs, gaps and opportunities** identified in Phase I

**and / or**

Phase II can **address new needs, gaps and opportunities** based external and internal input.

# Today's Agenda



The Common Fund



- **These are not “the new five initiatives.”** The structure and priorities of Phase II have not been determined.
- These topics and the underlying discussion questions were identified from **internal and external input** (including input from many of you).



# Before we move on to introductions...



*The Common Fund*

Are there any questions about

- **The NIH Common Fund,**
- **Phase I of the SCGE Program, or**
- **What we hope to achieve in today's workshop?**